Table 2 Summary of AEs related to treatment
From: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | Total | |
|---|---|---|---|---|---|---|
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
AE related to treatment | ||||||
Overall frequency | 6 (12%) | 16 (33%) | 11 (22%) | 1 (2%) | 0 (0%) | 34 (69%) |
Brain edema | 2 (4%) | 8 (16%) | 7 (14%) | 1 (2%) | 0 (0%) | 18 (37%) |
Headache | 4 (8%) | 9 (18%) | 2 (4%) | 0 (0%) | 0 (0%) | 15 (31%) |
Fatigue | 7 (14%) | 7 (14%) | 0 (0%) | 0 (0%) | 0 (0%) | 14 (29%) |
Dysphasia | 4 (8%) | 4 (8%) | 0 (0%) | 0 (0%) | 0 (0%) | 8 (16%) |
Hemiparesis | 0 (0%) | 2 (4%) | 4 (8%) | 0 (0%) | 0 (0%) | 6 (12%) |
Pyrexia | 5 (10%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 5 (10%) |
Decreased appetite | 3 (6%) | 1 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (8%) |
Myalgia | 2 (4%) | 2(4%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (8%) |
Nausea | 2 (4%) | 2(4%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (8%) |
SAE related to treatment | ||||||
Overall frequency | 0 (0%) | 4 (8%) | 9 (18%) | 1 (2%) | 0 (0%) | 14 (29%) |
Brain/vasogenic edema | 0 (0%) | 1 (2%) | 6 (12%) | 1 (2%) | 0 (0%) | 8 (16%) |
Dysphasia | 0 (0%) | 3 (6%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (6%) |
Hemiparesis | 0 (0%) | 0 (0%) | 3 (6%) | 0 (0%) | 0 (0%) | 3 (6%) |
